Eli Lilly obesity drug Zepbound significantly reduces obstructive sleep apnea severity
- 1Eli Lilly announced that its obesity drug Zepbound significantly reduced the severity of obstructive sleep apnea (OSA) in a clinical trial for patients with obesity.
- 2At week 52, the Zepbound group not using PAP therapy recorded an average AHI reduction of 21.1 per hour.
- 3Eli Lilly plans to apply for US approval of the daily pill for the treatment of moderate to severe obstructive sleep apnea by the end of the year.
So what's the key point?
Results show that Eli Lilly's obesity treatment can reduce breathing disturbances during sleep. If this drug receives approval, it can also be used as a treatment for sleep disorders.
Source CNBC +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.